WO2002092550A1 - Thyroid hormone receptor antagonists for cardiac and metabolic disorders ii - Google Patents

Thyroid hormone receptor antagonists for cardiac and metabolic disorders ii Download PDF

Info

Publication number
WO2002092550A1
WO2002092550A1 PCT/EP2002/004193 EP0204193W WO02092550A1 WO 2002092550 A1 WO2002092550 A1 WO 2002092550A1 EP 0204193 W EP0204193 W EP 0204193W WO 02092550 A1 WO02092550 A1 WO 02092550A1
Authority
WO
WIPO (PCT)
Prior art keywords
dibromo
phenyl
amino
propionate
triethylammonium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/004193
Other languages
English (en)
French (fr)
Inventor
Johan Malm
Peter Brandt
Karin Edvinsson
Thomas Ericsson
Sandra Gordon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karo Healthcare AB
Original Assignee
Karo Bio AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karo Bio AB filed Critical Karo Bio AB
Priority to US10/477,676 priority Critical patent/US7319096B2/en
Priority to EP02735262A priority patent/EP1387825A1/en
Priority to AU2002310850A priority patent/AU2002310850B2/en
Priority to KR10-2003-7014840A priority patent/KR20040017812A/ko
Priority to DE0001387825T priority patent/DE02735262T1/de
Priority to IL15867102A priority patent/IL158671A0/xx
Priority to CA002446747A priority patent/CA2446747A1/en
Priority to JP2002589436A priority patent/JP2004533450A/ja
Publication of WO2002092550A1 publication Critical patent/WO2002092550A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Definitions

  • amiodarone despite its complex pharmacokinetics, mode of action (amiodarone is not regarded as a pure class III agent) and numerous side effects, is currently considered by many to be the most effective agent in the control of both atrial and ventricular arrhythmia.
  • compounds of formula I are selected from:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/EP2002/004193 2001-05-15 2002-04-15 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ii Ceased WO2002092550A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US10/477,676 US7319096B2 (en) 2001-05-15 2002-04-15 Thyroid hormone receptor antagonists for cardiac and metabolic disorders II
EP02735262A EP1387825A1 (en) 2001-05-15 2002-04-15 Thyroid hormone receptor antagonists for cardiac & metabolic disorders ii
AU2002310850A AU2002310850B2 (en) 2001-05-15 2002-04-15 Thyroid hormone receptor antagonists for cardiac and metabolic disorders II
KR10-2003-7014840A KR20040017812A (ko) 2001-05-15 2002-04-15 심장병 환자 및 대사 장애를 위한 갑상선 호르몬 수용체길항근ⅱ
DE0001387825T DE02735262T1 (de) 2001-05-15 2002-04-15 Schilddrüsenhormon-rezeptor-antagonisten zur behandlung von herzerkrankungen & metabolischen störungen
IL15867102A IL158671A0 (en) 2001-05-15 2002-04-15 Benzyloxy derivatives and pharmaceutical compositions containing the same
CA002446747A CA2446747A1 (en) 2001-05-15 2002-04-15 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ii
JP2002589436A JP2004533450A (ja) 2001-05-15 2002-04-15 心臓障害および代謝障害のための甲状腺ホルモン受容体アンタゴニストii

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0111861.1 2001-05-15
GBGB0111861.1A GB0111861D0 (en) 2001-05-15 2001-05-15 Novel compounds

Publications (1)

Publication Number Publication Date
WO2002092550A1 true WO2002092550A1 (en) 2002-11-21

Family

ID=9914678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/004193 Ceased WO2002092550A1 (en) 2001-05-15 2002-04-15 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ii

Country Status (11)

Country Link
US (1) US7319096B2 (cg-RX-API-DMAC7.html)
EP (1) EP1387825A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004533450A (cg-RX-API-DMAC7.html)
KR (1) KR20040017812A (cg-RX-API-DMAC7.html)
CN (1) CN1275938C (cg-RX-API-DMAC7.html)
AU (1) AU2002310850B2 (cg-RX-API-DMAC7.html)
CA (1) CA2446747A1 (cg-RX-API-DMAC7.html)
DE (1) DE02735262T1 (cg-RX-API-DMAC7.html)
GB (1) GB0111861D0 (cg-RX-API-DMAC7.html)
IL (1) IL158671A0 (cg-RX-API-DMAC7.html)
WO (1) WO2002092550A1 (cg-RX-API-DMAC7.html)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084915A1 (en) * 2002-04-11 2003-10-16 Karo Bio Ab Novel thyroid receptor ligands
WO2005054213A1 (ja) * 2003-12-02 2005-06-16 Shionogi & Co., Ltd. ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体
WO2005094810A3 (en) * 2004-03-05 2006-01-12 Karobio Ab Novel pharmaceutical compositions
JPWO2004052861A1 (ja) * 2002-12-12 2006-04-13 興和株式会社 ヒドロキシアルキル環状ジアミン化合物
JP2007529567A (ja) * 2004-03-22 2007-10-25 カロ バイオ アクチェブラーグ 甲状腺受容体アゴニスト
US7514419B2 (en) 2003-11-19 2009-04-07 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
US10130643B2 (en) 2005-05-26 2018-11-20 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US11202789B2 (en) 2016-11-21 2021-12-21 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11787828B2 (en) 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US12678430B2 (en) 2020-06-09 2026-07-14 Viking Therapeutics, Inc. Compositions and methods for the treatment of liver disorders

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4705756B2 (ja) * 2002-02-07 2011-06-22 仁 遠藤 芳香族アミノ酸誘導体及び医薬組成物
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
BR112012021347A2 (pt) 2008-02-26 2019-09-24 Jenavalve Tecnology Inc stent para posicionamento e ancoragem de uma prótese valvular em um local de implantação no coração de um paciente
US10856978B2 (en) 2010-05-20 2020-12-08 Jenavalve Technology, Inc. Catheter system
CA2799459A1 (en) 2010-05-25 2011-12-01 Jenavalve Technology Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
WO2015028209A1 (en) 2013-08-30 2015-03-05 Jenavalve Technology Gmbh Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
EP4353203B1 (en) 2015-03-20 2026-08-19 JenaValve Technology, Inc. Heart valve prosthesis delivery system
EP3632378B1 (en) 2015-05-01 2024-05-29 JenaValve Technology, Inc. Device with reduced pacemaker rate in heart valve replacement
WO2017195125A1 (en) 2016-05-13 2017-11-16 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
EP3573579B1 (en) 2017-01-27 2023-12-20 JenaValve Technology, Inc. Heart valve mimicry
WO2024102411A1 (en) 2022-11-09 2024-05-16 Jenavalve Technology, Inc. Catheter system for sequential deployment of an expandable implant

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000353A1 (en) * 1997-06-27 1999-01-07 Karo Bio Ab Novel thyroid receptor ligands and method
WO2000007972A1 (en) * 1998-08-05 2000-02-17 Karo Bio Ab Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
WO2001036365A2 (en) * 1999-11-17 2001-05-25 Karo Bio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000353A1 (en) * 1997-06-27 1999-01-07 Karo Bio Ab Novel thyroid receptor ligands and method
WO2000007972A1 (en) * 1998-08-05 2000-02-17 Karo Bio Ab Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
WO2001036365A2 (en) * 1999-11-17 2001-05-25 Karo Bio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHIELLINI G ET AL: "A high-affinity subtype-selective agonist for the thyroid hormone receptor", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 5, no. 6, 1998, pages 299 - 306, XP002101080, ISSN: 1074-5521 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084915A1 (en) * 2002-04-11 2003-10-16 Karo Bio Ab Novel thyroid receptor ligands
JPWO2004052861A1 (ja) * 2002-12-12 2006-04-13 興和株式会社 ヒドロキシアルキル環状ジアミン化合物
JP4745666B2 (ja) * 2002-12-12 2011-08-10 興和株式会社 ヒドロキシアルキル環状ジアミン化合物
US7514419B2 (en) 2003-11-19 2009-04-07 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
WO2005054213A1 (ja) * 2003-12-02 2005-06-16 Shionogi & Co., Ltd. ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体
WO2005094810A3 (en) * 2004-03-05 2006-01-12 Karobio Ab Novel pharmaceutical compositions
JP2007529567A (ja) * 2004-03-22 2007-10-25 カロ バイオ アクチェブラーグ 甲状腺受容体アゴニスト
US10130643B2 (en) 2005-05-26 2018-11-20 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US10925885B2 (en) 2005-05-26 2021-02-23 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US11202789B2 (en) 2016-11-21 2021-12-21 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11787828B2 (en) 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US12227533B2 (en) 2018-03-22 2025-02-18 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US12678430B2 (en) 2020-06-09 2026-07-14 Viking Therapeutics, Inc. Compositions and methods for the treatment of liver disorders

Also Published As

Publication number Publication date
CA2446747A1 (en) 2002-11-21
US7319096B2 (en) 2008-01-15
EP1387825A1 (en) 2004-02-11
DE02735262T1 (de) 2004-07-08
GB0111861D0 (en) 2001-07-04
KR20040017812A (ko) 2004-02-27
CN1509267A (zh) 2004-06-30
CN1275938C (zh) 2006-09-20
US20040220147A1 (en) 2004-11-04
AU2002310850B2 (en) 2005-11-10
JP2004533450A (ja) 2004-11-04
IL158671A0 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
US7319096B2 (en) Thyroid hormone receptor antagonists for cardiac and metabolic disorders II
US7319163B2 (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
AU2002310850A1 (en) Thyroid hormone receptor antagonists for cardiac and metabolic disorders II
US20050171104A1 (en) Novel thyroid receptor ligands
AU2002237298B2 (en) Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
AU2002237298A1 (en) Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
US7279593B2 (en) Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
JP2003508380A (ja) スルホニルカルボキサミド誘導体、その調製方法および医薬としてのその使用
AU2002331145A1 (en) Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
US20040063781A1 (en) Compounds active at the glucocorticoid receptor II
EP1803452A1 (en) Ester derivative and pharmaceutical use thereof
CN1332921C (zh) 治疗心脏和代谢紊乱的主环取代的甲状腺受体拮抗物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002310850

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 158671

Country of ref document: IL

Ref document number: 2002735262

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2446747

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 028099419

Country of ref document: CN

Ref document number: 1020037014840

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002589436

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002735262

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10477676

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002310850

Country of ref document: AU